Ixchel Pharma ^Company

​Ixchel focuses on developing drugs that cure mitochondrial diseases for which there are currently no FDA-approved treatments. The majority of mitochondrial diseases are considered orphan and affect less than 200,000 people in the US. Ixchel has utilized a repurposing approach to isolate drugs for a number of debilitating orphan mitochondrialdiseases including Friedreich’s ataxia (FA), Mitochondrial Myopathy (MM), and Leber’s hereditary optic neuropathy (LHON).​